Technical Analysis for PAB - Patrys Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 0.009 | 12.50% | 0.001 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Flat | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 200 DMA | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 12.50% | |
Stochastic Reached Oversold | Weakness | 12.50% | |
Oversold Stochastic | Weakness | 12.50% | |
Fell Below 200 DMA | Bearish | 12.50% | |
Fell Below 50 DMA | Bearish | 12.50% | |
Narrow Range Bar | Range Contraction | 12.50% |
Alert | Time |
---|---|
Up 10% | about 7 hours ago |
Rose Above Previous Day's High | about 7 hours ago |
Rose Above 50 DMA | about 7 hours ago |
Rose Above 10 DMA | about 7 hours ago |
Up 1 ATR | about 7 hours ago |
Free Daily (Stock) Chart Reading
Patrys Limited Description
Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. It offers 3E10 Deoxymab, a lupus autoantibody. It is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Pharmaceutical Cancer Clinical Medicine Clinical Trial Biopharmaceutical Cancers Ducting Therapeutic Product Therapeutic Products Tumor Tumors Melanoma Solid Tumors Treatment Of Cancer Multiple Myeloma Pancreatic Cancer Pancreatic Cancers
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.0165 |
52 Week Low | 0.006 |
Average Volume | 1,102,973 |
200-Day Moving Average | 0.009 |
50-Day Moving Average | 0.009 |
20-Day Moving Average | 0.009 |
10-Day Moving Average | 0.009 |
Average True Range | 0.001 |
RSI (14) | 52.61 |
ADX | 16.02 |
+DI | 30.435 |
-DI | 30.435 |
Chandelier Exit (Long, 3 ATRs) | 0.008 |
Chandelier Exit (Short, 3 ATRs) | 0.010 |
Upper Bollinger Bands | 0.010 |
Lower Bollinger Band | 0.008 |
Percent B (%b) | 0.5 |
BandWidth | 24.444 |
MACD Line | 0.000 |
MACD Signal Line | 0.000 |
MACD Histogram | -0.0001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.009 | ||||
Resistance 3 (R3) | 0.009 | 0.009 | 0.009 | ||
Resistance 2 (R2) | 0.009 | 0.009 | 0.009 | 0.009 | |
Resistance 1 (R1) | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
Pivot Point | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
Support 1 (S1) | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
Support 2 (S2) | 0.009 | 0.009 | 0.009 | 0.009 | |
Support 3 (S3) | 0.009 | 0.009 | 0.009 | ||
Support 4 (S4) | 0.009 |